Emergent Biosolutions Inc.

63.12-2.88-4.36%Vol 1.77M1Y Perf -5.59%
Apr 22nd, 2021 16:00 DELAYED
BID62.04 ASK63.44
Open63.26 Previous Close66.00
Pre-Market63.12 After-Market-
 - -%  - -
Target Price
111.17 
Analyst Rating
Strong Buy 1.33
Potential %
76.12 
Finscreener Ranking
★★★★★     64.60
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     61.96
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     78.65
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap3.38B 
Earnings Rating
Buy
Price Range Ratio 52W %
2.77 
Earnings Date
29th Apr 2021

Today's Price Range

61.0064.47

52W Range

61.00137.61

5 Year PE Ratio Range

19.40133.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-18.70%
1 Month
-32.26%
3 Months
-41.08%
6 Months
-34.33%
1 Year
-5.59%
3 Years
15.65%
5 Years
55.54%
10 Years
167.80%

TickerPriceChg.Chg.%
EBS63.12-2.8800-4.36
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Financial StrengthValueIndustryS&P 500US Markets
2.20
3.10
0.37
0.60
14.00
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
66.30
28.20
35.60
20.40
23.77
RevenueValueIndustryS&P 500US Markets
1.36B
25.44
40.51
24.57
Earnings HistoryEstimateReportedSurprise %
Q04 20202.723.6734.93
Q03 20202.052.196.83
Q02 20200.531.98273.58
Q01 2020-0.020.01150.00
Q04 20191.671.57-5.99
Q03 20190.631.2192.06
Q02 20190.160.12-25.00
Q01 20190.13-0.13-200.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR1.55-83.17Negative
6/2021 QR2.13-68.68Negative
12/2021 FY9.28--
12/2022 FY5.06--
Next Report Date29th Apr 2021
Estimated EPS Next Report1.55
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.77M
Shares Outstanding53.58M
Trades Count19.22K
Dollar Volume65.98M
Avg. Volume740.37K
Avg. Weekly Volume1.38M
Avg. Monthly Volume1.12M
Avg. Quarterly Volume786.42K

Emergent Biosolutions Inc. (NYSE: EBS) stock closed at 63.12 per share at the end of the most recent trading day (a -4.36% change compared to the prior day closing price) with a volume of 1.77M shares and market capitalization of 3.38B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2200 people. Emergent Biosolutions Inc. CEO is Robert G. Kramer.

The one-year performance of Emergent Biosolutions Inc. stock is -5.59%, while year-to-date (YTD) performance is -29.55%. EBS stock has a five-year performance of 55.54%. Its 52-week range is between 61 and 137.61, which gives EBS stock a 52-week price range ratio of 2.77%

Emergent Biosolutions Inc. currently has a PE ratio of 13.70, a price-to-book (PB) ratio of 2.87, a price-to-sale (PS) ratio of 2.67, a price to cashflow ratio of 7.80, a PEG ratio of 2.32, a ROA of 11.26%, a ROC of 9.52% and a ROE of 23.18%. The company’s profit margin is 23.77%, its EBITDA margin is 35.60%, and its revenue ttm is $1.36 Billion , which makes it $25.44 revenue per share.

Of the last four earnings reports from Emergent Biosolutions Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.55 for the next earnings report. Emergent Biosolutions Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Emergent Biosolutions Inc. is Strong Buy (1.33), with a target price of $111.17, which is +76.12% compared to the current price. The earnings rating for Emergent Biosolutions Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Emergent Biosolutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Emergent Biosolutions Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.78, ATR14 : 5.09, CCI20 : -146.23, Chaikin Money Flow : -0.22, MACD : -10.69, Money Flow Index : 31.97, ROC : -20.35, RSI : 27.60, STOCH (14,3) : 9.95, STOCH RSI : 0.00, UO : 35.90, Williams %R : -90.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Emergent Biosolutions Inc. in the last 12-months were: Adam Havey (Option Excercise at a value of $1 524 812), Adam Havey (Sold 37 279 shares of value $3 701 646 ), Fuad El-Hibri (Option Excercise at a value of $2 099 892), Fuad El-Hibri (Sold 330 461 shares of value $31 416 928 ), George A. Joulwan (Sold 16 000 shares of value $1 830 013 ), Jerome M. Hauer (Sold 4 385 shares of value $373 373 ), Kathryn C. Zoon (Sold 13 506 shares of value $1 240 093 ), Louis W. Sullivan (Option Excercise at a value of $158 491), Louis W. Sullivan (Sold 28 418 shares of value $3 160 606 ), Robert G. Kramer (Option Excercise at a value of $2 523 699), Robert G. Kramer (Sold 88 555 shares of value $10 121 079 ), Ronald B. Richard (Option Excercise at a value of $316 983), Ronald B. Richard (Sold 58 274 shares of value $5 374 664 ), Sue Bailey (Sold 28 142 shares of value $2 882 988 ), Zsolt Harsanyi (Option Excercise at a value of $128 020), Zsolt Harsanyi (Sold 23 098 shares of value $2 577 378 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
6 (85.71 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (14.29 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.29
Strong Buy
1.33

Emergent Biosolutions Inc.

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

CEO: Robert G. Kramer

Telephone: +1 240 631-3200

Address: 400 Professional Drive, Gaithersburg 21079, MD, US

Number of employees: 2 200

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

51%49%

Bearish Bullish

51%49%

News

Stocktwits